Thermo Fisher Scientific Comprehensive Income 2010-2024 | TMO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Thermo Fisher Scientific comprehensive income for 2024 was $-2.697B, a 16.35% decline from 2023.
Thermo Fisher Scientific comprehensive income for 2023 was $-3.224B, a 4.03% increase from 2022.
Thermo Fisher Scientific comprehensive income for 2022 was $-3.099B, a 33.06% increase from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Thermo Fisher Scientific comprehensive income for 2024 was $-2.697B, a 16.35% decline from 2023.
Thermo Fisher Scientific comprehensive income for 2023 was $-3.224B, a 4.03% increase from 2022.
Thermo Fisher Scientific comprehensive income for 2022 was $-3.099B, a 33.06% increase from 2021.

Related Stocks
Company Name	Market Cap
Intuitive Surgical (ISRG)	$216.7B
Alcon (ALC)	$44.2B
Edwards Lifesciences (EW)	$44B
IDEXX Laboratories (IDXX)	$36.9B
DexCom (DXCM)	$35B
IQVIA Holdings (IQV)	$34.6B
Mettler-Toledo (MTD)	$27.3B
Waters (WAT)	$22.4B
STERIS (STE)	$21.8B
SONOVA HOLDING (SONVY)	$19.6B
Hologic (HOLX)	$14.4B
Fresenius Medical Care AG KGaA (FMS)	$13.6B
Penumbra (PEN)	$11.7B
Sysmex ADR (SSMXY)	$11.5B
Globus Medical (GMED)	$11.5B
Masimo (MASI)	$9.6B
Glaukos (GKOS)	$8.9B
Teleflex (TFX)	$8.1B
Integer Holdings (ITGR)	$4.8B
Inari Medical (NARI)	$4.7B
PROCEPT BioRobotics (PRCT)	$3.5B
Veracyte (VCYT)	$3.3B
Nihon Kohden (NHNKY)	$2.7B
TransMedics (TMDX)	$2.7B
LivaNova (LIVN)	$2.6B
Elekta AB (EKTAY)	$2.3B
Tandem Diabetes Care (TNDM)	$2.1B
Integra LifeSciences Holdings (IART)	$1.7B
Alphatec Holdings (ATEC)	$1.5B
Pulse Biosciences (PLSE)	$1.2B